Iterum Therapeutics (ITRM) Competitors $1.54 0.00 (0.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ITRM vs. PRQR, CRDF, CYBN, CGEN, SLN, ACRS, LYEL, SCPH, GNFT, and ALECShould you be buying Iterum Therapeutics stock or one of its competitors? The main competitors of Iterum Therapeutics include ProQR Therapeutics (PRQR), Cardiff Oncology (CRDF), Cybin (CYBN), Compugen (CGEN), Silence Therapeutics (SLN), Aclaris Therapeutics (ACRS), Lyell Immunopharma (LYEL), scPharmaceuticals (SCPH), Genfit (GNFT), and Alector (ALEC). These companies are all part of the "pharmaceutical products" industry. Iterum Therapeutics vs. ProQR Therapeutics Cardiff Oncology Cybin Compugen Silence Therapeutics Aclaris Therapeutics Lyell Immunopharma scPharmaceuticals Genfit Alector ProQR Therapeutics (NASDAQ:PRQR) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings. Which has higher earnings and valuation, PRQR or ITRM? ProQR Therapeutics has higher revenue and earnings than Iterum Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProQR Therapeutics$7.05M27.46-$30.43M-$0.32-7.41Iterum TherapeuticsN/AN/A-$38.37M-$2.00-0.77 Do insiders & institutionals have more ownership in PRQR or ITRM? 32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 9.2% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate PRQR or ITRM? ProQR Therapeutics presently has a consensus price target of $8.83, suggesting a potential upside of 272.71%. Iterum Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 224.68%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than Iterum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor PRQR or ITRM? In the previous week, ProQR Therapeutics had 1 more articles in the media than Iterum Therapeutics. MarketBeat recorded 1 mentions for ProQR Therapeutics and 0 mentions for Iterum Therapeutics. Iterum Therapeutics' average media sentiment score of 1.00 beat ProQR Therapeutics' score of 0.32 indicating that Iterum Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment ProQR Therapeutics Neutral Iterum Therapeutics Positive Which has more volatility & risk, PRQR or ITRM? ProQR Therapeutics has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Does the MarketBeat Community favor PRQR or ITRM? ProQR Therapeutics received 191 more outperform votes than Iterum Therapeutics when rated by MarketBeat users. However, 62.95% of users gave Iterum Therapeutics an outperform vote while only 61.71% of users gave ProQR Therapeutics an outperform vote. CompanyUnderperformOutperformProQR TherapeuticsOutperform Votes33261.71% Underperform Votes20638.29% Iterum TherapeuticsOutperform Votes14162.95% Underperform Votes8337.05% Is PRQR or ITRM more profitable? Iterum Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. Iterum Therapeutics' return on equity of 0.00% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ProQR Therapeutics-134.31% -71.58% -19.70% Iterum Therapeutics N/A N/A -160.85% SummaryProQR Therapeutics beats Iterum Therapeutics on 11 of the 18 factors compared between the two stocks. Get Iterum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITRM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITRM vs. The Competition Export to ExcelMetricIterum TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$42.38M$6.22B$5.21B$9.14BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-0.779.9189.4217.36Price / SalesN/A309.211,240.0477.11Price / CashN/A61.4443.7535.97Price / Book-3.216.055.314.79Net Income-$38.37M$154.90M$122.54M$225.00M7 Day Performance-3.75%1.35%1.42%2.37%1 Month Performance-12.99%0.41%2.50%4.40%1 Year Performance-18.95%3.08%25.29%20.10% Iterum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITRMIterum Therapeutics2.588 of 5 stars$1.54flat$5.00+224.7%-18.9%$42.38MN/A-0.7710Positive NewsPRQRProQR Therapeutics2.7586 of 5 stars$2.21-8.7%$8.83+299.7%+13.9%$180.51M$17.88M-6.91180CRDFCardiff Oncology2.1519 of 5 stars$3.47-3.9%$10.33+197.8%+128.5%$177.44M$688,000.00-3.6920Positive NewsCYBNCybin2.9391 of 5 stars$8.86-0.3%$138.00+1,457.6%N/A$177.13MN/A-1.3350Positive NewsCGENCompugen2.2714 of 5 stars$1.98+20.7%$4.00+102.0%+16.0%$176.69M$59.85M99.0070Positive NewsHigh Trading VolumeSLNSilence Therapeutics2.1072 of 5 stars$5.87-2.0%$57.20+874.4%-72.2%$175.68M$16.25M-3.74100ACRSAclaris Therapeutics4.0051 of 5 stars$2.45-0.8%$11.00+349.0%+125.4%$175.01M$27.08M-4.7186Short Interest ↑Positive NewsLYELLyell Immunopharma2.2103 of 5 stars$0.60-1.5%$1.00+68.1%-69.7%$173.84M$63,000.00-0.75270SCPHscPharmaceuticals3.335 of 5 stars$3.44+1.2%$15.00+336.0%-38.6%$172.14M$30.28M-1.8130GNFTGenfit1.646 of 5 stars$3.44-4.4%$13.00+277.9%+4.9%$171.99M$76.06M0.00120Short Interest ↑News CoveragePositive NewsALECAlector4.5046 of 5 stars$1.73-3.9%$3.75+116.8%-70.9%$169.42M$61.51M-1.02270Short Interest ↓ Related Companies and Tools Related Companies ProQR Therapeutics Alternatives Cardiff Oncology Alternatives Cybin Alternatives Compugen Alternatives Silence Therapeutics Alternatives Aclaris Therapeutics Alternatives Lyell Immunopharma Alternatives scPharmaceuticals Alternatives Genfit Alternatives Alector Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ITRM) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iterum Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Iterum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
